Are statins onco- suppressive agents for every type of tumor? A systematic review of literature

References

• Longo J, van Leeuwen JE, Elbaz M, et al. Statins as anticancer agents in the era of precision medicine. Clin Cancer Res. 2020 15;26(22):5791–5800. doi: 10.1158/1078-0432.CCR-20-1967
   PubMed Web of Science ®Google Scholar
• Warita K, Warita T, Beckwitt CH, et al. Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep. 2014;4(1):7593. doi: 10.1038/srep07593
   PubMedGoogle Scholar
• Yu R, Longo J, van Leeuwen JE, et al. Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins. Cancer Res. 2018;78(5):1347–1357. doi: 10.1158/0008-5472.CAN-17-1231
   PubMed Web of Science ®Google Scholar
• Kaymak I, Maier CR, Schmitz W, et al. Mevalonate pathway provides ubiquinone to maintain pyrimidine synthesis and survival in p53-deficient cancer cells exposed to metabolic stress. Cancer Res. 2020;80(2):189–203. doi: 10.1158/0008-5472.CAN-19-0650
   PubMed Web of Science ®Google Scholar
• Van de Donk NWCJ, Kamphuis MMJ, van Kessel B, et al. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood. 2003;1(9):3354–3362. doi: 10.1182/blood-2003-03-0970
   Google Scholar
• Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40(9–10):575–584. doi: 10.1016/j.clinbiochem.2007.03.016
   PubMed Web of Science ®Google Scholar
• Kidera Y, Tsubaki M, Yamazoe Y, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res. 2010;29(1):127. doi: 10.1186/1756-9966-29-127
   PubMedGoogle Scholar
• Choi M, Han J, Yang B, et al. Association of insulin, metformin, and statin with death in breast cancer patients. Cancer Res Treat. 2021;53(1):65–76. doi: 10.4143/crt.2020.430
   PubMed Web of Science ®Google Scholar
• Cardwell C, Hicks B, Hughes C, et al. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology. 2015;26(1):68–78. doi: 10.1097/EDE.0000000000000189
   PubMed Web of Science ®Google Scholar
• Ahern T, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103(19):1461–1468. doi: 10.1093/jnci/djr291
   PubMed Web of Science ®Google Scholar
• Kwan ML, Habel LA, Flick ED, et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109(3):573–579. doi: 10.1007/s10549-007-9683-8
   PubMed Web of Science ®Google Scholar
• Cho M, Yoo T, Jeong S, et al. Association of aspirin, metformin, and statin use with gastric cancer incidence and death: a nationwide cohort study. Cancer Prev Res (Phila). 2021;14(1):95–104. doi: 10.1158/1940-6207.CAPR-20-0123
   PubMed Web of Science ®Google Scholar
• Ung MH, MacKenzie TA, Onega TL, et al. Statins associate with improved death among patients with certain histological subtypes of lung cancer. Lung Cancer. 2018;126:89–96.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clin Transl Oncol. 2019;21(6):810–816. doi: 10.1007/s12094-018-1992-3
   PubMed Web of Science ®Google Scholar
• Huang B, Chang J, Li E, et al. Influence of statins and cholesterol on death among patients with pancreatic cancer. J Natl Cancer Inst. 2017;109(5):djw275. doi: 10.1093/jnci/djw275
   Google Scholar
• Voorneveld PW, Reimers MS, Bastiaannet E, et al. Statin use after diagnosis of colon cancer and patient survival. Gastroenterology. 2017;153(2):470–479. doi: 10.1053/j.gastro.2017.05.011
   PubMed Web of Science ®Google Scholar
• Verdoodt F, Kjaer Hansen M, Kjaer SK, et al. Statin use and death among ovarian cancer patients: a population-based cohort study. Int J Cancer. 2017;141(2):279–286. doi: 10.1002/ijc.30738
   PubMed Web of Science ®Google Scholar
• Couttenier A, Lacroix O, Vaes E, et al. Statin use is associated with improved survival in ovarian cancer: a retrospective population-based study. PLOS ONE. 2017;12(12):e0189233. doi: 10.1371/journal.pone.0189233
   PubMed Web of Science ®Google Scholar
• Sanfilippo K, Keller J, Gage B, et al. Statins are associated with reduced death in multiple myeloma. J Clin Oncol. 2016;34(33):4008–4014. doi: 10.1200/JCO.2016.68.3482
   PubMed Web of Science ®Google Scholar
• Cho S, Yang Y, Liu Y, et al. Previous exposure to statin may reduce the risk of subsequent non-Hodgkin lymphoma: a nationwide population-based case-control study. PLOS ONE. 2015;10(10):e0139289. doi: 10.1371/journal.pone.0139289
   PubMed Web of Science ®Google Scholar
• Smyth L, Blunt DN, Gatov E, et al. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population based study of 4913 subjects. Br J Haematol. 2020;191(3):396–404. doi: 10.1111/bjh.16635
   PubMed Web of Science ®Google Scholar
• Seliger C, Schaertl J, Gerken M, et al. Use of statins or NSAIDs and survival of patients with high-grade glioma. PLOS ONE. 2018;13(12):e0207858. doi: 10.1371/journal.pone.0207858
   PubMed Web of Science ®Google Scholar
• Seliger C, Meier C, Becker C, et al. Statin use and risk of glioma: population-based case–control analysis. Eur J Epidemiol. 2016;31(9):947–952. doi: 10.1007/s10654-016-0145-7
   PubMed Web of Science ®Google Scholar
• Cote D, Rosner B, Smith-Warner S, et al. Statin use, hyperlipidemia, and risk of glioma. Eur J Epidemiol. 2019;34(11):997–1011. doi: 10.1007/s10654-019-00565-8
   PubMed Web of Science ®Google Scholar
• Tan N, Klein EA, Li J, et al. Statin use and risk of prostate cancer in a population of men who underwent biopsy. J Urol. 2011;186(1):86–90. doi: 10.1016/j.juro.2011.03.004
   PubMed Web of Science ®Google Scholar
• Allott EH, Ebot EM, Stopsack KH, et al. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin Cancer Res. 2020;26(5):1086–1093. doi: 10.1158/1078-0432.CCR-19-2853
   PubMed Web of Science ®Google Scholar
• Jespersen C, Norgaard M, Friis S, et al. Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997–2010. Cancer Epidemiol. 2014;38(1):42–47. doi: 10.1016/j.canep.2013.10.010
   PubMed Web of Science ®Google Scholar
• Sperling C, Verdoodt F, Friis S, et al. Statin use and risk of endometrial cancer: a nationwide registry-based case–control study. Acta Obstet Gynecol Scand. 2017;96(2):144–149. doi: 10.1111/aogs.13069
   PubMed Web of Science ®Google Scholar
• Baandrup L, Dehlendorff C, Friis S, et al. Statin use and risk for ovarian cancer: a Danish nationwide case–control study. Br J Cancer. 2015;112(1):157–161. doi: 10.1038/bjc.2014.574
   PubMed Web of Science ®Google Scholar
• Lebo N, Griffiths R, Hall S, et al. Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. Head Neck. 2018;40(8):1697–1706. doi: 10.1002/hed.25152
   PubMed Web of Science ®Google Scholar
• Spoerl S, Gerken M, Fischer R, et al. Statin use ameliorates survival in oral squamous cell carcinoma—data from a population-based cohort study applying propensity score matching. Biomedicines. 2023;11(2):369. doi: 10.3390/biomedicines11020369
   PubMed Web of Science ®Google Scholar
• Saka-Herrán C, Jané-Salas E, Mano-Azul A, et al. Effects of the prior use of statins on head and neck cancer risk: a hospital-based case–control study. Pharmaceuticals. 2022;15(5):579. doi: 10.3390/ph15050579
   Web of Science ®Google Scholar
• Getz KR, Bellile E, Zarins KR, et al. Statin use and head and neck squamous cell carcinoma outcomes. Int J Cancer. 2021;148(10):2440–2448. doi: 10.1002/ijc.33441
   PubMed Web of Science ®Google Scholar
• Bjarnadottir O, Romero Q, Bendahl P-O, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138(2):499–508. doi: 10.1007/s10549-013-2473-6
   PubMed Web of Science ®Google Scholar
• Feldt M, Bjarnadottir O, Kimbung S, et al. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial Signe Borgquist. J Transl Med. 2015;13(1):133. doi: 10.1186/s12967-015-0486-0
   PubMedGoogle Scholar
• Yulian ED, Siregar NC. Bajuadji Combination of Simvastatin and FAC improves response to neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Res Treat. 2021;53(4):1072–1083. doi: 10.4143/crt.2020.1024
   PubMed Web of Science ®Google Scholar
• Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer breast cancer res treat. Breast Cancer Res Treat. 2010;119(1):137–144. doi: 10.1007/s10549-009-0507-x
   PubMed Web of Science ®Google Scholar
• Alarfi H, Youssef LA, Salamoon MA. Prospective, randomized, placebo-controlled study of a combination of simvastatin and chemotherapy in metastatic breast cancer. J Oncol. 2020;4174395. doi: 10.1155/2020/4174395
   Google Scholar
• Dewidar SA, Hamdy O, Eltantawy A, et al. Effect of concomitant use of pitavastatin with neoadjuvant Chemoth. protocols in breast cancer patients: A randomized controlled clinical trial. Saudi Pharm. 2022;30(10):1486–1496. doi: 10.1016/j.jsps.2022.07.011
   PubMed Web of Science ®Google Scholar
• Kim ST, Kang JH, Lee J, et al. Simvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. Eur J Cancer. 2014;50(16):2822–2830. doi: 10.1016/j.ejca.2014.08.005
   PubMed Web of Science ®Google Scholar
• Konings IR, van der Gaast A, van der Wijk LJ, et al. The addition of pravastatin to Chemoth. In advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer. 2010;46(18):3200–3204. doi: 10.1016/j.ejca.2010.07.036
   PubMed Web of Science ®Google Scholar
• Yang P, Tsai Y, Chen K, et al. Statin use improves overall survival of patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: a nationwide matched cohort study. Cancers (Basel). 2020;12:2055. doi: 10.3390/cancers12082055
   PubMed Web of Science ®Google Scholar
• Han JY, Lee SH, Yoo NJ, et al. A randomized phase ii study of Gefitinib Plus Simvastatin versus Gefitinib alone in previously treated patients with advanced non–small cell lung cancer. Clin Cancer Res. 2011;17(6):1553–1560. doi: 10.1158/1078-0432.CCR-10-2525
   PubMed Web of Science ®Google Scholar
• Hung M, Chen I, Lee C, et al. Statin improves survival in patients with EGFR-TKI lung cancer: a nationwide population based study. PLOS ONE. 2017;12(2):e0171137. doi: 10.1371/journal.pone.0171137
   PubMed Web of Science ®Google Scholar
• Chou CW, Lin CH, Hsiao TH, et al. Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis. Europe PMC. 2019;9(1):20403. doi: 10.1038/s41598-019-56532-6
   Google Scholar
• Jouve JL, Lecomte T, Bouche O, et al. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(3):516–522. doi: 10.1016/j.jhep.2019.04.021
   PubMed Web of Science ®Google Scholar
• Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001;84(7):886–891. doi: 10.1054/bjoc.2000.1716
   PubMed Web of Science ®Google Scholar
• Lee J, Hong YS, Hong JY, et al. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab invest new drugs. Invest New Drugs. 2014;32(3):535–541. doi: 10.1007/s10637-014-0065-x
   PubMed Web of Science ®Google Scholar
• Baas JM, Krens LL, ten Tije AJ, et al. Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients invest new drugs. Invest New Drugs. 2015;33(6):1242–1247. doi: 10.1007/s10637-015-0285-8
   PubMed Web of Science ®Google Scholar
• Lim SH, Kim TW, Hong YS, et al. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. Br J Cancer. 2015;113(10):1421–1426. doi: 10.1038/bjc.2015.371
   PubMed Web of Science ®Google Scholar
• Kim Y, Tae Kim TW, Han SW, et al. A single arm, phase II study of simvastatin plus XELOX and Bevacizumab as first-line chemotherapy in metastatic colorectal cancer patients. Cancer Res Treat. 2019;51(3):1128–1134. doi: 10.4143/crt.2018.379
   PubMed Web of Science ®Google Scholar
• Chen HY, Wang Q, Xu Q-H, et al. Statin as a combined th. for advanced-stage ovarian cancer: a propensity score matched analysis. Biomed Res Int. 2016;2016:1–5. doi: 10.1155/2016/9125238
   Web of Science ®Google Scholar
• Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007;109(7):2999–06. doi: 10.1182/blood-2006-08-044446
   PubMed Web of Science ®Google Scholar
• Shadman M, Mawad R, Dean C, et al. Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2015;90(6):483–486. doi: 10.1002/ajh.23981
   PubMed Web of Science ®Google Scholar
• Hus M, Grzasko N, Szostek M, et al. Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Ann Hematol. 2011;90(10):1161–1166. doi: 10.1007/s00277-011-1276-2
   PubMed Web of Science ®Google Scholar
• Gordon JA, Buonerba C, Pond G, et al. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget. 2018;9(28):19861–19873. doi: 10.18632/oncotarget.24888
   PubMedGoogle Scholar
• Boegemann M, Schlack K, Fischer A-K, et al. Influence of statins on survival outcome in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate. PLOS ONE. 2016;11(9):e0161959. doi: 10.1371/journal.pone.0161959
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Sonpavde G, Pond G, et al. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol Focus. 2018;4(6):874–879. doi: 10.1016/j.euf.2017.03.015
   PubMedGoogle Scholar
• Lopez H, Gomez J, Torres L, et al. Influence of statins on survival outcome in patients with metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors inter. J Radiat Oncol Biol Phys. 2019;105(1):E278–E279. doi: 10.1016/j.ijrobp.2019.06.1908
   Web of Science ®Google Scholar
• Longo J, Hamilton RJ, Masoomian M, et al. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):630–637. doi: 10.1038/s41391-020-0221-7
   PubMed Web of Science ®Google Scholar
• Goard CA, Chan-Seng-Yue M, Mullen PJ, et al. Identifying molecular features that distinguish fluvastatin- sensitive breast tumor cells. Breast Cancer Res Treat. 2014;143(2):301–312. doi: 10.1007/s10549-013-2800-y
   PubMed Web of Science ®Google Scholar
• Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119(1):137–144. doi: 10.1007/s10549-009-0507-x
   PubMed Web of Science ®Google Scholar
• Ingallina E, Sorrentino G, Bertolio R, et al. Mechanical cues control mutant p53 stability through a mevalonate–RhoA axis. Nat Cell Biol. 2018 Jan;20(1):28–35.
   PubMed Web of Science ®Google Scholar
• Longo J, Mullen PJ, Yu R, et al. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Mol Metab. 2019;25:119–130. doi: 10.1016/j.molmet.2019.04.003
   PubMed Web of Science ®Google Scholar
• Jiang W, Hu JW, He XR, et al. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241. doi: 10.1186/s13046-021-02041-2
   PubMed Web of Science ®Google Scholar
• Menter DG, Ramsauer VP, Harirforoosh S, et al. Differential effects of pravastatin and Simvastatin on the growth of tumor cells from different organ sites. PLoS ONE. 2011;6(12):e28813. doi: 10.1371/journal.pone.0028813
   PubMed Web of Science ®Google Scholar
• Knuuttila E, Riikonen J, Syvala H, et al. Access and concentrations of atorvastatin in the prostate in men with prostate cancer. Prostate. 2019;79(12):1427–1434. doi: 10.1002/pros.23863
   Web of Science ®Google Scholar
• Jameson MB, Kirsten K, Espinoza D, et al. SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. BMC Cancer. 2019;19(1):1229. doi: 10.1186/s12885-019-6405-7
   PubMed Web of Science ®Google Scholar